Literature DB >> 16763864

[Early antiexudative response--OCT monitoring after intravitreal bevacizumab injection].

M Völcker1, S Peters, W Inhoffen, F Ziemssen.   

Abstract

VEGF is more potent than histamine by a factor of 50,000 for inducing increased vessel permeability. Already in the first few minutes, hydraulic conductivity and diffusive permeability are significantly increased, followed by a longer-lasting, marked leakage over 20 h. Specific inhibition of the angiogenic, vasoactive, and permeability-inducing protein VEGF is now possible by new drugs, one of which is the first available (off-label) treatment in Germany for routine clinical use (Avastin). Retinal edema is composed of increased outflow of water and low molecular substances in the interstitial environment and is an important determinate of functional development in different ocular diseases. First experiences with the anti-hyperpermeability effect show early response and high potential in pathologic leakage. Future examinations have to assess when a permanent benefit can be achieved in respect to the other antiproliferative capabilities of the drug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16763864     DOI: 10.1007/s00347-006-1356-1

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  45 in total

1.  Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization.

Authors:  F Gelisken; W Inhoffen; M Partsch; U Schneider; I Kreissig
Journal:  Am J Ophthalmol       Date:  2001-04       Impact factor: 5.258

2.  Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using StratusOCT.

Authors:  Lelia A Paunescu; Joel S Schuman; Lori Lyn Price; Paul C Stark; Siobahn Beaton; Hiroshi Ishikawa; Gadi Wollstein; James G Fujimoto
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-06       Impact factor: 4.799

3.  Diurnal variation in clinically significant diabetic macular edema measured by the Stratus OCT.

Authors:  Antonio Polito; Michele Del Borrello; Giovanni Polini; Francesca Furlan; Miriam Isola; Francesco Bandello
Journal:  Retina       Date:  2006-01       Impact factor: 4.256

4.  Time course and morphology of vascular effects associated with photodynamic therapy.

Authors:  Ursula Schmidt-Erfurth; Marc Niemeyer; Wolfgang Geitzenauer; Stephan Michels
Journal:  Ophthalmology       Date:  2005-12       Impact factor: 12.079

5.  Pathophysiological consequences of VEGF-induced vascular permeability.

Authors:  Sara M Weis; David A Cheresh
Journal:  Nature       Date:  2005-09-22       Impact factor: 49.962

6.  Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability.

Authors:  Patrice M Becker; Johannes Waltenberger; Robin Yachechko; Tamara Mirzapoiazova; James S K Sham; Chun Geun Lee; Jack A Elias; Alexander D Verin
Journal:  Circ Res       Date:  2005-05-26       Impact factor: 17.367

7.  Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.

Authors:  Yaning Wang; David Fei; Martin Vanderlaan; An Song
Journal:  Angiogenesis       Date:  2005-05-09       Impact factor: 9.596

8.  VEGF-induced permeability increase is mediated by caveolae.

Authors:  Y Feng; V J Venema; R C Venema; N Tsai; M A Behzadian; R B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-01       Impact factor: 4.799

9.  VEGF transiently disrupts gap junctional communication in endothelial cells.

Authors:  S Suarez; K Ballmer-Hofer
Journal:  J Cell Sci       Date:  2001-03       Impact factor: 5.285

10.  Endothelial contraction induced by histamine-type mediators: an electron microscopic study.

Authors:  G Majno; S M Shea; M Leventhal
Journal:  J Cell Biol       Date:  1969-09       Impact factor: 10.539

View more
  4 in total

1.  Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.

Authors:  Leigh Spielberg; Anita Leys
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-04       Impact factor: 3.117

2.  [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress].

Authors:  D Kook; A Wolf; A S Neubauer; C Haritoglou; S G Priglinger; A Kampik; M W Ulbig
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

3.  [Intraocular injections of bevacizumab in rare indications--two cases].

Authors:  T Wecke; C Knop; W Schreiber; W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

Review 4.  [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].

Authors:  C H Meyer; H-M Helb; N Eter
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.